Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
Zacks News
Is a Surprise in the Cards for Teva (TEVA) in Q2 Earnings?
by Zacks Equity Research
While the inclusion of sales from Actavis Generics acquisition may continue to pull up Teva Pharmaceutical Industries Ltd.'s (TEVA) sales, its generic segment may see weakness.
Nektar's NKTR-181 Positive in Human Abuse Potential Study
by Zacks Equity Research
Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
by Zacks Equity Research
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed disodium).
VIVUS Settles with Teva on Weight Management Drug Generic
by Zacks Equity Research
VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.
Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) and Korean partner Celltrion, Inc., announced that the FDA has accepted for review their Biologics License Application (BLA) for CT-P10, a proposed biosimilar to Roche Holding AG's (RHHBY) Rituxan (rituximab).
Alder's Shares Dip Despite Positive Migraine Trial Results
by Zacks Equity Research
Alder Biopharmaceuticals, Inc.'s (ALDR) shares plummeted almost 28% despite the announcement of positive top line results from phase III study, evaluating its lead pipeline candidate eptinezumab for prevention of frequent episodic migraine.
Teva/Xenon Nerve Pain Candidate Fails in Phase II Study
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that a mid-stage study evaluating their pipeline candidate, topical TV-45070 for post-herpetic neuralgia (PNH) did not meet the primary endpoint.
Allergan Continues to Focus on Acquisitions and Branded Unit
by Zacks Equity Research
We issued an updated research report on Allergan plc (AGN) on Jun 23.
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.
Pfizer & Lilly Get Fast Track Designation for Pain Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).
Teva Migraine Candidate Succeeds in Second Phase III Study
by Zacks Equity Research
Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.
Regeneron Announces Positive Data on Carcinoma Candidate
by Zacks Equity Research
Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).
Teva's Migraine Candidate TEV-48125 Positive in Phase III
by Zacks Equity Research
Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).
Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab
by Zacks Equity Research
Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg tablets.
Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.
Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint
by Zacks Equity Research
Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies
Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.
Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan
by Zacks Equity Research
Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period
Teva (TEVA) Q1 Earnings In-Line, Sales Miss, Shares Up
by Zacks Equity Research
Teva???s first quarter earnings (including equity compensation expenses), came in at $1.03 per share, in-line with the consensus estimate.
Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?
by Swarup Gupta
Mylan and Teva are scheduled to report on May 10 and May 11
Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View
by Zacks Equity Research
Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.
Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11
Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.